STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRDA
  4. [Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Entrada Therapeutics holder sells 86,914 shares

Entrada Therapeutics, Inc. (TRDA) had indirect shareholders affiliated with the MPM BioVentures funds report open-market sales of its common stock.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) had indirect shareholders affiliated with the MPM BioVentures funds report open-market sales of its common stock. Across three transactions on August 27, 28 and 31, 2026, entities including MPM BioVentures 2014, L.P., MPM BioVentures 2018, L.P. and related funds sold a total of 86,914 shares at weighted average prices ranging from about $6.76 to $7.37 per share. After the August 31 transaction, shares were held among these entities as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 86,914 shs ($616K)
Type Security Shares Price Value
Sale Common Stock F8, F9, F4, F10 44,259 $6.99 $309K
Sale Common Stock F5, F6, F4, F7 3,733 $7.01 $26K
Sale Common Stock F1, F2, F3, F4 38,922 $7.20 $280K
Holdings After Transaction: Common Stock — 4,231,434 shares (Indirect, See Footnote)
Footnotes (10)
  1. F1. The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. F3. The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.
  4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  5. F5. The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.
  6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. F7. The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.
  8. F8. The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.
  9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  10. F10. The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.
Total shares sold 86,914 shares Aggregate sales of Entrada Therapeutics common stock reported across 3 transactions
Shares sold on 2026-08-27 38,922 shares Open-market or private sale of common stock on August 27, 2026
Shares sold on 2026-08-28 3,733 shares Open-market or private sale of common stock on August 28, 2026
Shares sold on 2026-08-31 44,259 shares Open-market or private sale of common stock on August 31, 2026
Weighted average price 2026-08-27 $7.20 per share Weighted average sale price; individual trades ranged from $6.88 to $7.37
Weighted average price 2026-08-28 $7.01 per share Weighted average sale price; individual trades ranged from $6.95 to $7.24
Weighted average price 2026-08-31 $6.99 per share Weighted average sale price; individual trades ranged from $6.76 to $7.1626
weighted average sale price financial
"Price represents the weighted average sale price of the shares sold."
beneficial ownership financial
"Each Reporting Person disclaims beneficial ownership of the securities except..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his or its respective pecuniary interest therein."
indirect financial
"transaction_type non-derivative, ownership_type indirect, ownership_code I"

FAQ

What insider activity did TRDA report in this Form 4?
Affiliated MPM BioVentures funds reported three open-market sales of Entrada Therapeutics common stock on August 27, 28 and 31, 2026, totaling 86,914 shares sold at weighted average prices between approximately $6.76 and $7.37 per share.

How many TRDA shares were sold on each reported date?
On August 27, 2026, affiliated entities sold 38,922 shares; on August 28, 2026 they sold 3,733 shares; and on August 31, 2026 they sold 44,259 shares of Entrada Therapeutics common stock, all reported as indirect sales by MPM-related entities.

What prices did insiders receive for the TRDA shares sold?
The reported Form 4 shows weighted average sale prices of $7.20, $7.01 and $6.99 per share for the three transactions, with detailed footnotes stating sale price ranges of $6.88–$7.37, $6.95–$7.24 and $6.76–$7.1626 per share, respectively.

Who executed the TRDA share sales disclosed in this filing?
The sales were executed by entities affiliated with MPM BioVentures, including MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P. and MPM Asset Management Investors BV2018 LLC.

How many TRDA shares do the MPM-affiliated entities hold after these transactions?
After the August 31, 2026 transaction, the Form 4 states holdings of 1,921,425 shares by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.

Are the TRDA sales under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5-1 checkbox is not checked, and the filing does not state that these transactions were effected pursuant to a Rule 10b5-1 trading plan or other pre-arranged trading arrangement.

Do the reporting persons claim full beneficial ownership of the TRDA shares?
No. The Form 4 states that each reporting person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest in the shares held by the affiliated MPM entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/27/2026S38,922(1)D$7.2(2)4,279,426ISee Footnote(3)(4)
Common Stock08/28/2026S3,733(5)D$7.01(6)4,275,693ISee Footnote(4)(7)
Common Stock08/31/2026S44,259(8)D$6.99(9)4,231,434ISee Footnote(4)(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
EVNIN LUKE
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
GADICKE ANSBERT
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Foley Todd
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM Asset Management Investors BV2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 GP LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BIOVENTURES 2018 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.
4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.
6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.
8. The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.
9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.
Remarks:
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Luke Evnin08/31/2026
/s/ Ansbert Gadicke08/31/2026
/s/ Todd Foley08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.08/31/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR